Growth Hormone · 0.1mg × 10 vials
In plain terms: IGF-1 LR3 is a research compound - injectable, fast-acting and well studied.
IGF-1 LR3 (Long R3 IGF-1) is a synthetic, modified version of insulin-like growth factor 1, the downstream peptide that does most of the actual tissue-growth work after growth hormone signals the liver. Two changes from native IGF-1: an arginine substitution at position 3 (replacing the glutamic acid, hence "R3"), and a 13-amino-acid extension on the N-terminus (the "Long" part), bringing total length to 83 aa vs the 70 of endogenous IGF-1. Both changes serve one purpose: dramatically reduce binding affinity to the six IGF binding proteins (IGFBPs) that normally trap circulating IGF-1 and shut it down within minutes. The result is a molecule that escapes IGFBP sequestration, stays free in circulation, hits IGF-1 receptors on muscle and other tissues for ~20-30 hours instead of ~10 minutes, and is roughly 2-3x more potent than native IGF-1 on a per-molecule basis. Downstream, IGF-1R activation drives the PI3K/AKT/mTOR pathway (the master switch for muscle protein synthesis), MAPK signaling for satellite cell proliferation, and GLUT4 translocation for glucose uptake. Translation: protein synthesis up, satellite cells (the muscle stem cells that fuse into existing fibers) activated, nutrient partitioning toward muscle, glucose pulled into muscle cells aggressively. The aggressive glucose uptake is also the source of the hypoglycemia risk that defines the dosing rules.
Typical dose ranges by experience level - educational reference. Message us and we tailor it to you.
Eat a carb-containing meal 15-30 min pre-injection. New researchers commonly report a "head-rush" or lightheaded feeling 20-40 min post-injection if blood glucose drops, that's the signal to eat more carbs around the dose next time. First-cycle reads are subtle, mostly pump quality, recovery between sessions, and ~2-4 lb scale weight (largely glycogen + water). Don't chase dramatic visual changes on a 4-week first cycle.
This is the "working dose" band where most users see visible recomp effects when paired with a hypertrophy training block and surplus calories. Bodyfat shifts are modest, the compound is muscle-anabolic, not lipolytic. Hypoglycemia management is non-negotiable at this band, especially if researcher trains fasted. Lower-back/joint pain is a moderate-frequency report at 50+ mcg, often described as a "growing pains" sensation, generally resolves at dose reduction.
100 mcg is the practical ceiling. Doubling above this does not double results, the dose-response curve flattens hard above 80 mcg, and side effect severity rises near-linearly past that point. Advanced researchers running 80-100 mcg almost always stack with HGH or CJC+Ipa for synergistic GH-axis activation and report the IGF-1 LR3 portion is what drives the recovery and visible muscle fullness rather than the GH portion (which contributes more to fat loss and connective tissue).
Straight talk - what people actually report, and what the studies measured.
Peer-reviewed studies and clinical guidelines - tap any to read the source.
](https://pubmed.ncbi.nlm.nih.gov/7561636/) - foundational paper on LR3 variant pharmacology and IGFBP-evasion
Read study ↗PubMedIGF-1 and its monitoring in medical diagnostic and in sports (PMC7913862)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7913862/) - comprehensive review of IGF-1 biology + sports use + WADA detection context
Read study ↗PubMedEffect of IGF1 on Myogenic Proliferation and Differentiation of Bovine Skeletal Muscle Satellite Cells via PI3K/AKT (PMC11675145)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11675145/) - satellite cell activation mechanism
Read study ↗PubMedmIGF-1-Induced Hypertrophy and Ca2+ Handling in Differentiated Satellite Cells (PMC4168228)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4168228/) - hypertrophy pathway evidence
Read study ↗PubMedObesity and endocrine-related cancer: the role of IGF-1 (PMC9899991)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9899991/) - IGF-1 + cancer risk biology
Read study ↗Clinical guidelinesOxford 400k cohort, IGF-1 and cancer riskchronic elevation cancer signal
Read study ↗Aggregated sentiment from public forums & socials - real-world reports, not individual endorsements.
Hypoglycemia/blood sugar crashes: the most-reported side effect, manageable with pre-injection carb meal; users who skip the carbs and inject fasted report dizziness, sweats, brain fog 30-60 min post-dose
Lower back / joint pain: moderate-frequency, "growing pains" sensation at 50+ mcg, often resolves at dose reduction or with hydration + electrolyte focus
Pump quality / vascularity: reported by majority of users within first 1-2 weeks, often the first sign the compound is working
Numbness/tingling in fingers: lower-frequency report, similar to carpal tunnel sensation from water retention + IGF-1 mediated tissue effects
Gut growth ("IGF gut"): the bodybuilding-forum folk-claim that high-dose IGF-1 LR3 causes visceral organ growth and a distended abdomen. Reality is the "GH gut" / "palumboism" look is far more often attributable to high-dose HGH + insulin + slin pin use, not IGF-1 LR3 at research doses (20-100 mcg). At standard doses this is largely a myth.
Localized growth at injection site: pure folklore. IGF-1 LR3 distributes systemically within minutes. Bilateral biceps injection does not selectively grow biceps.
Route: SubQ (intramuscular sometimes used by advanced researchers; site-specific local growth from IM is folklore, the molecule distributes systemically within minutes regardless of injection site)
Injection site: rotate abdomen and outer thigh subQ; if researcher insists on IM the "bilateral injection into trained muscle group post-workout" protocol exists in the forum literature but local effect is unproven
Storage: refrigerated, ~14-21 days after reconstitution (IGF-1 LR3 is less stable post-recon than the GLP-1s, use sooner). Pre-recon vials: refrigerated, freezer for long storage
Notes: Always eat a meal containing carbs 15-30 minutes before injection. Hypoglycemia is the #1 acute risk and it's real, not theoretical. Most common admin window is immediately post-workout (when nutrient partitioning is most favorable and glycogen-uptake bias is highest), but timing-around-workout matters less than people claim. Slow-wall injection technique (1 ml over 20-30 seconds) is recommended at reconstitution to avoid protein denaturation from shear stress. Do not shake the vial, swirl gently.